The Senior Manager, Marketing and Corporate Strategy will play a pivotal role in shaping the commercial direction of Lexeo’s leading cardiac programs and organization. With multiple catalysts expected in 2026, it is crucial to define and refine commercial assumptions as lead programs advance, and to support the expansion of Lexeo’s growing commercial organization and capabilities. This role focuses on characterizing the current and evolving landscape in gene therapy and rare cardiovascular disease, particularly Friedreich ataxia (FA) cardiomyopathy and arrhythmogenic cardiomyopathy (ACM). Additionally, this role will encompass corporate strategy responsibilities, supporting commercial development, pipeline strategy and prioritization and other high-impact projects with senior executives as Lexeo evolves.